Viatris Inc. (NASDAQ:VTRS) is highlighted as one of the 13 Best Healthcare Stocks to Buy Under $10. Goldman Sachs reiterated a Hold rating with a price target of $10.00. The company reported $3.3 billion in total revenues in fiscal Q1 2025, primarily impacted by negative Indore Impact. Excluding this, revenues would have increased by 2%.

Viatris Inc. (NASDAQ:VTRS) generated $67 million in new product revenues in fiscal Q1 2025 and anticipates delivering new product revenues between $450 million to $550 million in 2025. The company offers healthcare and pharmaceutical products across various therapeutic areas, operating in Developed Markets, Greater China, JANZ, and Emerging Markets segments.

Although Viatris Inc. (NASDAQ:VTRS) shows potential as an investment, other AI stocks may offer greater upside potential with less downside risk. For those interested in an undervalued AI stock benefiting from Trump-era tariffs and onshoring trend, a free report on the best short-term AI stock is available. No disclosures mentioned in the article.

Read more at Yahoo Finance: Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT